| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/30/2005 | US20050142132 Prevention and treatment of amyloidogenic disease |
| 06/30/2005 | US20050142130 Use of angiotensin-(1-7) for preventing and/or reducing the formation of neointima |
| 06/30/2005 | US20050142129 Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor |
| 06/30/2005 | US20050142128 Treatment for diseases of the eye inner ear and central nervous system |
| 06/30/2005 | US20050142126 Useful in the diagnosis and/or treatment of several diseases, particularly lung injuries and diseases as well as oxidative stress-related disorders, particularly neurotoxic injury or exitotoxic injury such as osteoarthritis |
| 06/30/2005 | US20050142124 Nutrient compositions and methods for enhanced effectiveness of the immune system |
| 06/30/2005 | US20050142120 Cells expressing anti-Fc receptor binding components |
| 06/30/2005 | US20050142117 Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation |
| 06/30/2005 | US20050142116 In a subject suffering from a disorder characterized by increased cell proliferation or by co-infection with mycoplasma and a second microbe; administering an agent that prevents sialic acid- mediated attachment of mycoplasma cells |
| 06/30/2005 | US20050142112 Administering recombinant adenoviral vector comprising a nucleic acid encoding p53 tumor suppressor protein; gene expression; contacting cells polyprenyl-protein transferase inhibitor FPT39; breast, colorectal, pancreatic, or prostate gland cancer treatment; antitumor and antimetastasis agents |
| 06/30/2005 | US20050142110 For diagnosis, prevention, or treatment of diseases responsive to therapy with interferon- beta; free of human serum albumin; stability |
| 06/30/2005 | US20050142109 Method of treatment using interferon-tau |
| 06/30/2005 | US20050142108 Methods of modulating cytokine activity; related reagents |
| 06/30/2005 | US20050142106 Mutant interleukin-2 (IL-2) polypeptides |
| 06/30/2005 | US20050142104 Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
| 06/30/2005 | US20050142103 Mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood by administration of an inhibitor of GTPases such as Rac1 and Rac2 alone or in combination; specifically, methods are disclosed for mobilizing hematopoietic stem cells into subject's peripheral blood; treating cancer, anemia |
| 06/30/2005 | US20050142102 Administering a hematopoietic growth factor such as granulocyte-colony stimulating factor and granulocyte-macrophage colony stimulating factor to a mammal; providing neuroprotection to the neural cells involved or to induce neurogenesis to recover from neuronal loss |
| 06/30/2005 | US20050142101 Chemically modified peptides derived from the chemokine CCL14 (HCC-1) can be used; replacement of the ultimate N-terminal amino acid of CCL14[9-74] by nonanoic acid (NNY) converts it into a potent agonist; inactivation of the chemokine receptor; antiinflammatory agents |
| 06/30/2005 | US20050142100 Tumor Necrosis Factor Binding Protein (TBP) or an isoform, mutein, fused protein, function derivative, active fraction, or salt; multiple sclerosis; corticosteroid; glatiramer |
| 06/30/2005 | US20050142098 Polyoxyethylene glycol conjugated neublastin polypeptide dimers; exhibit prolonged bioavailability |
| 06/30/2005 | US20050142081 Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least on matrix metalloproteinase inhibitor |
| 06/30/2005 | US20050142078 Method of stimulation of melanin production and induction of skin tanning |
| 06/30/2005 | US20050142076 Dental viscous pharmaceutical containing basic fibroblast growth factor |
| 06/30/2005 | US20050142069 Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
| 06/30/2005 | US20050142068 Retinal toxicity screening methods |
| 06/30/2005 | US20050142062 Novel method of diagnosing and treating gliomas |
| 06/30/2005 | US20050139211 Introducing aerosol into a ventilator |
| 06/30/2005 | DE10355408A1 Use of a C1-esterase inhibitor comprising a sialic-acid-containing glycoprotein that neutralizes viruses and their toxic components pathogenic to human, for diagnosing, treating and preventing acute viral infections |
| 06/30/2005 | DE10351149A1 Oligoribonukleotide zur Behandlung von unerwünschter Pigmentierung der Haut und der Haare durch RNA-Interferenz Oligoribonucleotides for the treatment of undesired pigmentation of the skin and the hair by RNA interference |
| 06/30/2005 | CA2588965A1 Novel chimeric plasminogen activators and their pharmaceutical use |
| 06/30/2005 | CA2551039A1 Analogues of glp-1 |
| 06/30/2005 | CA2550695A1 Glp-1 pharmaceutical compositions |
| 06/30/2005 | CA2550581A1 Antimicrobial composition comprising a peptide derived from k-casein and a divalent cation |
| 06/30/2005 | CA2550505A1 Copper antagonist compounds |
| 06/30/2005 | CA2550058A1 Pharmaceutical composition comprising a tgf-beta2 antisense oligonucleotide and a chemotherapeutic |
| 06/30/2005 | CA2550050A1 Novel glp-1 analogues linked to albumin-like agents |
| 06/30/2005 | CA2550013A1 Bactericide against streptococcus mutans and streptococcus sobrinus |
| 06/30/2005 | CA2549874A1 Antibacterial macrocycles with substituted biphenyl |
| 06/30/2005 | CA2549593A1 Stabilised compositions of factor vii polypeptides |
| 06/30/2005 | CA2549582A1 Novel glp-1 compounds |
| 06/30/2005 | CA2549573A1 Dna sequence, and recombinant preparation of group 4 major allergens from cereals |
| 06/30/2005 | CA2549529A1 Helical synthetic peptides that stimulate cellular cholesterol efflux |
| 06/30/2005 | CA2549486A1 Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases |
| 06/30/2005 | CA2549386A1 Methods for synthesis of encoded libraries |
| 06/30/2005 | CA2549303A1 Novel sodium channel |
| 06/30/2005 | CA2549167A1 Inhibitors of hepatitis c virus ns3/ns4a serine protease |
| 06/30/2005 | CA2549052A1 Isozyme-specific antagonists of protein kinase c |
| 06/30/2005 | CA2549011A1 Compositions comprising two different populations of polymer-active agent conjugates |
| 06/30/2005 | CA2549000A1 Method for treating neurological disorders |
| 06/30/2005 | CA2548773A1 A treatment for necrotizing enterocolitis |
| 06/30/2005 | CA2548585A1 Treatment of viral infections |
| 06/30/2005 | CA2548282A1 Methods and compositions for inhibiting c-met dimerization and activation |
| 06/30/2005 | CA2548100A1 Methods and compositions for treatment of interferon-resistant tumors |
| 06/30/2005 | CA2547822A1 Stabilized interferon liquid formulations |
| 06/30/2005 | CA2547737A1 Peptides having an ace inhibiting effect |
| 06/30/2005 | CA2547635A1 A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1 |
| 06/30/2005 | CA2546979A1 A biological active blood serum, methods of producing it and uses thereof |
| 06/30/2005 | CA2545671A1 Brachyspira pilosicoli 72kda outer-membrane protein and diagnostic and therapeutic uses thereof |
| 06/30/2005 | CA2491338A1 A method for inhibiting the growth of gastrointestinal tract tumors |
| 06/29/2005 | EP1548435A1 Diagnostic and examination method for eating disorder |
| 06/29/2005 | EP1548130A1 Fen endonucleases |
| 06/29/2005 | EP1548118A2 Complementary adenoviral vector systems and cell lines |
| 06/29/2005 | EP1548031A1 Nature-identical erythropoietin |
| 06/29/2005 | EP1548029A2 Peptid- and peptide mimetic derivatives having integrin inhibitor properties III |
| 06/29/2005 | EP1548028A1 Substituted type peptides of wt1 |
| 06/29/2005 | EP1548027A1 Compound binding to leukocytes and medicinal composition containing the compound in labeled state as the active ingredient |
| 06/29/2005 | EP1548026A1 Novel depsipeptide compound |
| 06/29/2005 | EP1548024A1 Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| 06/29/2005 | EP1547626A2 Carrier with solid fibrinogen and solid thrombin |
| 06/29/2005 | EP1547618A1 Drug for auditory dysfunction |
| 06/29/2005 | EP1547617A1 Arthrodial cartilage extracellular matrix degradation inhibitor |
| 06/29/2005 | EP1547609A1 Embryo implantation inhibitor |
| 06/29/2005 | EP1546727A2 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a (pde11a) |
| 06/29/2005 | EP1546726A2 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 06/29/2005 | EP1546451A1 Apparatus and method for automatically defibering and extracting kraft pulp from old corrugated cardboard |
| 06/29/2005 | EP1546409A2 Method for diagnosing chronic myeloid leukemia |
| 06/29/2005 | EP1546379A2 Modulation of ptp1b signal transduction by rna interference |
| 06/29/2005 | EP1546377A2 Methods and compositions to treat pain and painful disorders using 9949, 14230, 760, 62553, 41897, 47174, 33408, 10002,16209, 314, 636, 27410, 33260, 619,15985, 69112, 2158, 224, 615, 44373, 95431, 22245, 2387, 16658, 55054, 9569 or 13424 molecules |
| 06/29/2005 | EP1546362A1 Apolipoprotein e stable folding intermediate and methods of use thereof |
| 06/29/2005 | EP1546341A1 Mipp1 homologous nucleic acids and proteins involved in the regulation of energy homeostatis |
| 06/29/2005 | EP1546338A1 Polynucleotides and polypeptides derived from lactobacillus rhamnosus hn001 |
| 06/29/2005 | EP1546331A2 Integrase cofactor |
| 06/29/2005 | EP1546324A1 Expression vectors encoding epitopes of target-associated antigens |
| 06/29/2005 | EP1546323A2 Transgenic cells transfected with pituitary tumor transforming gene (pttg) expression vectors and uses therefor |
| 06/29/2005 | EP1546235A2 Water-soluble polymer alkanals |
| 06/29/2005 | EP1546202A1 Human coagulation factor vii polypeptides |
| 06/29/2005 | EP1546201A2 Nucleic acid sequences encoding novel point mutations on mglur2 and mglur3. |
| 06/29/2005 | EP1546200A2 Stabilized exendin-4 compounds |
| 06/29/2005 | EP1546199A2 Novel chemokine-like polypeptides |
| 06/29/2005 | EP1546198A1 Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap) |
| 06/29/2005 | EP1546196A1 Marker for cancer |
| 06/29/2005 | EP1546193A1 Pegylated t1249 polypeptide |
| 06/29/2005 | EP1546190A2 Hbv mutations associated with reduced susceptibility to adefovir |
| 06/29/2005 | EP1546188A2 P53 binding t cell receptor molecules and uses thereof |
| 06/29/2005 | EP1546184A2 Human immunosuppressive protein |
| 06/29/2005 | EP1546182A2 Compositions and methods for the diagnosis and treatment of tumor |
| 06/29/2005 | EP1546179A2 Antisense modulation of polo-like kinase expression |
| 06/29/2005 | EP1546175A1 Group b streptococcal phage lysin |
| 06/29/2005 | EP1546174A2 Methods and compositions for rna interference |
| 06/29/2005 | EP1546172A2 Control sequences of the human corin gene |